论文部分内容阅读
近日,美国FDA批准注射用美曲普汀(metreleptin,Myalept)作为瘦素缺乏的替代性治疗药物,用于先天性或获得性全身脂肪代谢障碍患者的并发症治疗。全身脂肪代谢障碍是一种与脂肪组织缺乏有关的病症。先天性全身脂肪代谢障碍患者出生时脂肪组织很少或根本没有。后天获得性全身脂肪代谢障碍患者通常随着时间的推移脂肪组织流失。因瘦素由脂肪组织分泌,所以全身脂肪代谢障碍患者的瘦素水平很低。瘦素可调控进食及胰岛素等激素水平。本品为重组瘦素类似物,一项标签开放性试验评
Recently, the United States FDA approved the use of metreleptin (Myalept) as an alternative treatment of leptin deficiency for the treatment of complications in patients with congenital or acquired systemic lipodystrophy. Whole body lipodystrophy is a condition associated with a deficiency of adipose tissue. Patients with congenital systemic lipodystrophy have little or no adipose tissue at birth. Acquired fatty acid metabolism in patients with acquired obesity is usually lost over time. Because leptin is secreted by adipose tissue, leptin levels are low in patients with systemic lipodystrophy. Leptin can regulate the hormone levels such as eating and insulin. This product is recombinant leptin analogs, a label open test evaluation